Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1094413

A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis


Jeličić, Mario-Livio; Brusač, Edvin; Amidžić Klarić, Daniela; Nigović, Biljana; Turk, Nikša; Mornar Ana
A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis // Scientific reports, 10 (2020), 1; 20838, 10 doi:10.1038/s41598-020-77654-2 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1094413 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis
(A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis)

Autori
Jeličić, Mario-Livio ; Brusač, Edvin ; Amidžić Klarić, Daniela ; Nigović, Biljana ; Turk, Nikša ; Mornar Ana

Izvornik
Scientific reports (2045-2322) 10 (2020), 1; 20838, 10

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
HPLC ; biomimetic chromatography ; assay

Sažetak
Medication adherence is an important factor in infammatory bowel disease therapy, which includes regular supplementation of malabsorbed vitamins. Absorption of folic acid is limited due to the damaging of the gastrointestinal tract, which can increase the chances to develop megaloblastic anaemia and colorectal cancer. In this work, 5- aminosalicylates (mesalazine, balsalazide, sulfasalazine and olsalazine) and folic acid were characterized regarding their pharmacokinetic related properties (hydrophobicity, phospholipid and plasma protein binding) using the biomimetic chromatographic approach. Despite the high binding percentage of 5-aminosalicylates for human serum albumin (> 61.44%), results have shown that folic acid binding to human serum albumin protein is far greater (69.40%) compared to α1-acid-glycoprotein (3.45%). Frontal analysis and zonal elution studies were conducted to provide an insight into the binding of folic acid to human serum albumin and potential competition with 5-aminosalicylates. The analytical method for the simultaneous determination of assay in proposed fxed-dose combinations was developed and validated according to ICH Q2 (R1) and FDA method validation guidelines. Separation of all compounds was achieved within 16 min with satisfactory resolution (Rs> 3.67) using the XBridge Phenyl column (150 × 4.6 mm, 3.5 µm). High linearity (r> 0.9997) and precision (RSD< 2.29%) was obtained, whilst all recoveries were within the regulatory defned range by British (100.0± 5.0%) and United States Pharmacopeia (100.0 ± 10.0%).

Izvorni jezik
Engleski

Znanstvena područja
Kemija, Farmacija



POVEZANOST RADA


Projekti:
UIP-2017-05-3949 - Razvoj naprednih analitičkih metoda za lijekove i biološki aktivne tvari u liječenju upalnih bolesti crijeva (IBDAnalytics) (Mornar Turk, Ana, HRZZ - 2017-05) ( CroRIS)

Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb

Poveznice na cjeloviti tekst rada:

doi www.nature.com

Citiraj ovu publikaciju:

Jeličić, Mario-Livio; Brusač, Edvin; Amidžić Klarić, Daniela; Nigović, Biljana; Turk, Nikša; Mornar Ana
A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis // Scientific reports, 10 (2020), 1; 20838, 10 doi:10.1038/s41598-020-77654-2 (međunarodna recenzija, članak, znanstveni)
Jeličić, M., Brusač, E., Amidžić Klarić, D., Nigović, B., Turk, N. & Mornar Ana (2020) A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis. Scientific reports, 10 (1), 20838, 10 doi:10.1038/s41598-020-77654-2.
@article{article, author = {Jeli\v{c}i\'{c}, Mario-Livio and Brusa\v{c}, Edvin and Amid\v{z}i\'{c} Klari\'{c}, Daniela and Nigovi\'{c}, Biljana and Turk, Nik\v{s}a}, year = {2020}, pages = {10}, DOI = {10.1038/s41598-020-77654-2}, chapter = {20838}, keywords = {HPLC, biomimetic chromatography, assay}, journal = {Scientific reports}, doi = {10.1038/s41598-020-77654-2}, volume = {10}, number = {1}, issn = {2045-2322}, title = {A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis}, keyword = {HPLC, biomimetic chromatography, assay}, chapternumber = {20838} }
@article{article, author = {Jeli\v{c}i\'{c}, Mario-Livio and Brusa\v{c}, Edvin and Amid\v{z}i\'{c} Klari\'{c}, Daniela and Nigovi\'{c}, Biljana and Turk, Nik\v{s}a}, year = {2020}, pages = {10}, DOI = {10.1038/s41598-020-77654-2}, chapter = {20838}, keywords = {HPLC, biomimetic chromatography, assay}, journal = {Scientific reports}, doi = {10.1038/s41598-020-77654-2}, volume = {10}, number = {1}, issn = {2045-2322}, title = {A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis}, keyword = {HPLC, biomimetic chromatography, assay}, chapternumber = {20838} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font